Mar 30, 2023 04:08PM
Mar 30, 2023 04:05PM
Nov 3, 2022 07:33AM
Nov 3, 2022 07:30AM
Aug 12, 2022 07:16AM
Aug 12, 2022 07:15AM
Aug 4, 2022 04:05PM Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
May 17, 2022 07:37AM
Apr 29, 2022 07:37AM
Apr 20, 2022 07:47AM
Apr 20, 2022 07:47AM
Apr 7, 2022 07:01AM
Apr 7, 2022 07:00AM
Mar 23, 2022 04:05PM Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights
Feb 28, 2022 07:25AM
Feb 9, 2022 07:00AM
Jan 6, 2022 07:37AM
Dec 16, 2021 07:37AM
Oct 27, 2021 06:47AM
Aug 10, 2021 04:10PM
Jun 15, 2021 04:10PM Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder
May 13, 2021 04:05PM
May 10, 2021 07:57AM
Apr 29, 2021 06:55AM
Apr 29, 2021 06:47AM
Mar 24, 2021 04:05PM
Jan 19, 2021 08:31AM
Jan 4, 2021 07:59AM Aptinyx (APTX) Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy
Jan 4, 2021 07:57AM
Nov 12, 2020 04:03PM
Oct 21, 2020 09:27AM
Oct 20, 2020 05:33PM
Oct 19, 2020 04:45PM
Oct 19, 2020 04:44PM
Sep 28, 2020 08:27AM Aptinyx (APTX) Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia
Sep 28, 2020 08:27AM
Jul 8, 2020 08:37AM
Jun 18, 2020 07:59AM
Jun 18, 2020 07:57AM
Jun 18, 2020 07:57AM
Mar 30, 2020 04:01PM
Mar 30, 2020 04:01PM Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Dec 9, 2019 04:05PM
Dec 9, 2019 04:05PM
Nov 12, 2019 04:01PM
Nov 12, 2019 04:01PM
Nov 12, 2019 07:39AM
Nov 12, 2019 07:27AM
Nov 12, 2019 07:27AM Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
Oct 28, 2019 07:57AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All